C4 Therapeutics, Inc.
cemsidomide
Multiple Myeloma
Countdown
724days
Phase 2 readout · ~ Jun 30, 2028 estimated
What's at stake
Phase 2 trial results for cemsidomide in Multiple Myeloma are due ~ Jun 30, 2028. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Mid-2028: Present ORR data and indices of durability and safety for the Phase 2 MOMENTUM trial”